Document is current
Any future updates will be listed below
-
Authors
Hegyesi, Hargita http://orcid.org/0000-0002-8800-5169
Pallinger, Éva http://orcid.org/0000-0002-5789-0951
Mecsei, Szabina
Hornyák, Balázs
Kovácsházi, Csenger
Brenner, Gábor B.
Giricz, Zoltán
Pálóczi, Krisztina
Kittel, Ágnes http://orcid.org/0000-0002-6888-7731
Tóvári, József http://orcid.org/0000-0002-5543-3204
Turiak, Lilla http://orcid.org/0000-0002-2139-8156
Khamari, Delaram
Ferdinandy, Péter http://orcid.org/0000-0002-6424-6806
Buzás, Edit I. http://orcid.org/0000-0002-3744-206X
-
Funding
Funding for this research was provided by:
nemzeti kutatási, fejlesztési és innovaciós alap (NVKP_16-1-2016-0017, VEKOP-2.3.2-16-2016-000002, VEKOP-2.3.3-15-2017-00016, Higher Education Excellence Program (FIKP) Therapeutic Thematic Programme, TKP2020-NKA-26, VEKOP-2.3.3-15-2016-00006)
hungarian scientific research fund (OTKA K120237)
horizon 2020 framework programme (H2020-MSCA-ITN-2017-722148, 739593)
Semmelweis University
- License Information
-
More Information
Article History
Received: 15 July 2021
Revised: 15 December 2021
Accepted: 29 December 2021
First Online: 20 January 2022
Declarations
:
: EIB is a member of the Advisory Board of Sphere Gene Therapeutics Inc. (Boston, MA, US). PF is the founder and CEO of Pharmahungary Group, a group of R&D companies.
: The animal experiments were carried out with ethics approval (PE/EA/1426-7/2018). All animal studies were conducted according to the 1998 XXVIII Hungarian law about animal protection and welfare.
: All authors (HH, ÉP, SzM, BH, CsK, GBB, ZG, KP, ÁK, JT, LT, DK, PF, and EIB) gave consent to participate in this study. All authors (HH, ÉP, SzM, BH, CsK, GBB, ZG, KP, ÁK, JT, LT, DK, PF, and EIB) agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
: All authors (HH, ÉP, SzM, BH, CsK, GBB, ZG, KP, ÁK, JT, LT, DK, PF, and EIB) approved the version to be published.
